Targeting epidermal growth factor receptor in lung cancer
- 1 July 2002
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 4 (4) , 317-324
- https://doi.org/10.1007/s11912-002-0007-1
Abstract
Among the most promising agents in clinical development to treat non-small-cell lung cancer (NSCLC) are the epidermal growth factor receptor (EGFR) targeting agents. A series of recent studies have demonstrated the activity of anti-EGFR targeted therapies for NSCLC. In advanced NSCLC that is refractory to chemotherapy, antitumor responses have been reported with EGFR tyrosine kinase inhibitors (ZD1839 and OSI-774). The role of ZD1839 and OSI-774 as possible additions to standard chemotherapy in the first-line setting has also been evaluated, and the studies conducted to date should respond to the question of whether these compounds could provide a survival benefit. Other areas of research involve looking at the role of EGFR tyrosine kinase inhibitors in the neoadjuvant treatment of stage III NSCLC and the planning of chemoprevention studies. These exciting results and plans are further complemented by an emerging number of compounds in clinical development, including both monoclonal antibodies (ie, IMC-C225) and other tyrosine kinase inhibitors, directed at the EGFR.Keywords
This publication has 25 references indexed in Scilit:
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.2002
- CI-1033, a pan-erbB tyrosine kinase inhibitorSeminars in Oncology, 2001
- Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839Seminars in Oncology, 2001
- Targeting the epidermal growth factor receptor: a clinical reality.2001
- Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.2001
- ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic resultsEuropean Journal Of Cancer, 2001
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- Regulation of signal transduction and signal diversity by receptor oligomerizationTrends in Biochemical Sciences, 1994